Daniel Olson, MD

Real-world studies show TIL therapy drives durable melanoma responses with no new safety concerns, but many patients miss eligibility.

Experts unpack real-world TIL therapy results, who qualifies, and how to sequence lifileucel after immunotherapy or BRAF for metastatic melanoma.

Daniel Olson, MD, discusses findings with brenetafusp from a phase 1/2 trial (NCT04262466) in patients with advanced melanoma.

Daniel Olson, MD, discusses the benefit associated with lifileucel in patients with unresectable or metastatic melanoma.

Daniel Olson, MD, discusses toxicities associated with lifileucel and IL-2 in patients with unresectable or metastatic melanoma.

Daniel Olson, MD, discusses the FDA approval of lifileucel for patients with advanced melanoma whose disease has been previously treated.